Medicus, Vol. 27 No. 1 Debljina i ..., 2018.
Pregledni rad
Reslizumab, a New Therapy Option for Patients with Severe Eosinophilic Asthma
Neven Tudorić
Sažetak
Available epidemiological data suggest that 3-10% of asthmatic patients suffer from severe asthma. Despite the adequate administration of standard inhalation therapy, the implementation of measures controlling environmental factors and appropriate compliance, it is not possible to achieve satisfactory control of the disease in these patients. A significant number of these patients have severe eosinophilic asthma in which the allergen-independent eosinophilic form of inflammatory reaction in the airway represents a major etiopathogenetic mechanism. Two biological drugs with a strong anti-eosinophilic effect have recently become available for these patients. These drugs, reslizumab and mepolizumab, are monoclonal antibodies directed against interleukin 5 (IL-5). They signifficantly improve pulmonary function, reduce the number of acute asthma aggravations, reduce the need to administer systemic corticosteroids, and improve the reduced quality of life in asthmatic patients. Anti-eosinophilic drugs are effective in a well-defined subgroup of patients with severe asthma. Therefore, prior to deciding on the administration of these drugs, careful patient screening based on phenotypic characteristics of asthma should be made.
Ključne riječi
severe asthma; eosinophilic asthma; eosinophils; anti-eosinophilic drugs; reslizumab; mepolizumab
Hrčak ID:
199428
URI
Datum izdavanja:
26.4.2018.
Posjeta: 2.815 *